Lysosomal Proteins as a Therapeutic Target in Neurodegeneration
Jessica M. Mc Donald, Dimitri Krainc
Index: 10.1146/annurev-med-050715-104432
Full Text: HTML
Abstract
Several proteins that are mutated in lysosomal storage diseases are linked to neurodegenerative disease. This review focuses on some of these lysosomal enzymes and transporters, as well as current therapies that have emerged from the lysosomal storage disease field. Given the deeper genetic understanding of lysosomal defects in neurodegeneration, we explore why some of these orphan disease drug candidates are also attractive targets in subpopulations of individuals with neurodegenerative disease.
Latest Articles:
Gene Editing: A New Tool for Viral Disease
2017-01-18
[10.1146/annurev-med-051215-031129]
2017-01-18
[10.1146/annurev-med-050715-104506]
Esophageal Adenocarcinoma: Screening, Surveillance, and Management
2017-01-18
[10.1146/annurev-med-050715-104218]
Management of Rectal Cancer Without Radical Resection
2017-01-18
[10.1146/annurev-med-062915-021419]
The End of Nihilism: Systemic Therapy of Advanced Non–Small Cell Lung Cancer
2017-01-18
[10.1146/annurev-med-042915-102442]